Johnson & Johnson

JNJ

270.24 (1.36%) 3.67

Health Care

Pharmaceuticals

Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of a range of products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as oncology immunology neuroscience pulmonary hypertension infectious diseases and cardiovascular and metabolism distributed through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery orthopedic cardiovascular and vision fields distributed through wholesalers hospitals and retailers and used in the professional fields by physicians nurses hospitals eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction trauma spine sports related injuries and others as well as open laparoscopic and robotic surgical procedures; instrumentation energy devices stapling systems wound closure biosurgery products and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick New Jersey.

Quality Checklist 6/8

5Y Shares Out Change < 0%

ROIC > 10%

Debt/Equity < 1

Current Ratio > 1

Net Margin > 10%

Est. EPS Growth > 5%

Quick Ratio > 1

Past Net Income CAGR > 0%

0.0%of Portfolio

My holdings

Day change:

Total change:

Cost basis:

Market cap: $651.25(B)

EV: $679.53(B)

Total Equity: $84.97(B)

Earnings date: Oct-13-2026

P/E: 30.92

Forward P/E: 24.46

P/FCF: 29.25

P/S: 6.64

P/B: 7.66

EPS: $8.7

EPS (fwd): $11.1

FCF/share: $9.2

Revenue/share: $40.7

Book value/share: $35.3

ROIC: 21.7%

ROA: 13.5%

ROE: 33.6%

Debt/Equity: 0.58

Current Ratio: 1.10

Gross margin: 68.1%

Operating margin: 26.2%

Net margin: 21.5%

Dividend/share: $5.2

Div. yield: 1.94%

All Valuation Overview Growth Financials & KPIs Competitors & Peer Comparison Ownership Tools

JNJ Valuation & Price Targets

Current Price

$270

Favorite Valuation Methods

PEvaluation

N/A

Analyst targets

N/A

DCF (2-stage)

N/A

More Valuation Methods

DCF (simple)

N/A

DCF (exit mult.)

N/A

DDM

N/A

EPS growth

N/A

Revenue growth

N/A

Peter Lynch FV

N/A

Graham No.

N/A

PEvaluation

12% overvalued

Low

$179

Mid

$239

High

$299

Current price

$270

Fair P/E

Margin of safety

EPS

Market Model

Economic moat: Wide

EPS Estimates

	Low	Avg	High	#
FY+1	11.0	11.1	11.1	4
FY+2	11.3	12.3	13.5	4
FY+3	15.1	15.3	15.5	2
FY+4	18.0	18.1	18.1	2
FY+5	20.3	20.6	21.0	2

Analyst Price Targets

4% undervalued

Low

$190

Mid

$280

High

$305

Current price

$270

Analyst Recommendations

Strong Buy5

Buy11

Hold6

Sell1

Strong Sell0

2-stage DCF

First Stage Duration: 5 Years

Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh

Terminal Growth Rate
LowMidHigh

Discount Rate

Discounted Cash Flow

Forecast years: 5 Years

Terminal Growth Rate
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years

Exit FCF Multiple
LowMidHigh

Discount Rate

Free cash flow estimates:

Y+1 est.

Y+2 est.

0.00%

Y+3 est.

0.00%

Y+4 est.

0.00%

Y+5 est.

0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years

First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years

Starting EPS
EPS Growth Rate
LowMidHigh

Final P/E
LowMidHigh

Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years

Base Revenue
Revenue Growth Rate
LowMidHigh

Final Net Margin
LowMidHigh

Final P/E Ratio
LowMidHigh

Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate

About

Terms & privacy

Price charts & news courtesy of TradingView

Blog

Contact